Harshal Deshmukh, Emmanuel Ssemmondo, Kazeem Adeleke, Shiva Mongolu, Mo Aye, Steve Orme, Daniel Flanagan, Prakash Abraham, Claire Higham, Thozhukat Sathyapalan, UK Acromegaly Register Study (UKAR) Group
{"title":"肢端肥大症患者的首次缓解时间和存活率：来自英国渐冻人症登记研究（UKAR）的证据。","authors":"Harshal Deshmukh, Emmanuel Ssemmondo, Kazeem Adeleke, Shiva Mongolu, Mo Aye, Steve Orme, Daniel Flanagan, Prakash Abraham, Claire Higham, Thozhukat Sathyapalan, UK Acromegaly Register Study (UKAR) Group","doi":"10.1111/cen.15112","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>This study aimed to understand the effect of time to remission of acromegaly on survival in people living with acromegaly.</p>\n </section>\n \n <section>\n \n <h3> Design, Patients and Measurement</h3>\n \n <p>This cross-sectional study used data from the UK Acromegaly Register. We considered remission of acromegaly growth hormone controlled at ≤2 μg/L following the diagnosis of acromegaly. We used the accelerated failure time model to assess the effect of time to remission on survival in acromegaly.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The study population comprises 3569 individuals with acromegaly, with a median age of diagnosis of 47.3 (36.5–57.8) years, 48% females and a majority white population (61%). The number of individuals with the first remission of acromegaly was 2472, and the median time to first remission was 1.92 (0.70–6.58) years. In this study, time to first remission in acromegaly was found to have a significant effect on survival (<i>p</i> < .001); for every 1-year increase in time to first remission, there was a median 1% reduction in survival in acromegaly. In an analysis adjusted for covariates, the survival rate was 52% higher (<i>p</i> < .001) in those who underwent surgery as compared to those who did not have surgery, 18% higher (<i>p</i> = .01) in those who received treatment with somatostatin analogues (SMA) as compared to those with dopamine agonists and 21% lower (<i>p</i> < .001) in those who received conventional radiotherapy as compared to those who did not receive radiotherapy.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>In conclusion, this population-based study conducted in patients with acromegaly revealed that faster remission time, surgical intervention and treatment with SMA are linked to improved survival outcomes.</p>\n </section>\n </div>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Time to first remission and survival in patients with acromegaly: Evidence from the UK Acromegaly Register Study (UKAR)\",\"authors\":\"Harshal Deshmukh, Emmanuel Ssemmondo, Kazeem Adeleke, Shiva Mongolu, Mo Aye, Steve Orme, Daniel Flanagan, Prakash Abraham, Claire Higham, Thozhukat Sathyapalan, UK Acromegaly Register Study (UKAR) Group\",\"doi\":\"10.1111/cen.15112\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>This study aimed to understand the effect of time to remission of acromegaly on survival in people living with acromegaly.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Design, Patients and Measurement</h3>\\n \\n <p>This cross-sectional study used data from the UK Acromegaly Register. We considered remission of acromegaly growth hormone controlled at ≤2 μg/L following the diagnosis of acromegaly. We used the accelerated failure time model to assess the effect of time to remission on survival in acromegaly.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>The study population comprises 3569 individuals with acromegaly, with a median age of diagnosis of 47.3 (36.5–57.8) years, 48% females and a majority white population (61%). The number of individuals with the first remission of acromegaly was 2472, and the median time to first remission was 1.92 (0.70–6.58) years. In this study, time to first remission in acromegaly was found to have a significant effect on survival (<i>p</i> < .001); for every 1-year increase in time to first remission, there was a median 1% reduction in survival in acromegaly. In an analysis adjusted for covariates, the survival rate was 52% higher (<i>p</i> < .001) in those who underwent surgery as compared to those who did not have surgery, 18% higher (<i>p</i> = .01) in those who received treatment with somatostatin analogues (SMA) as compared to those with dopamine agonists and 21% lower (<i>p</i> < .001) in those who received conventional radiotherapy as compared to those who did not receive radiotherapy.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>In conclusion, this population-based study conducted in patients with acromegaly revealed that faster remission time, surgical intervention and treatment with SMA are linked to improved survival outcomes.</p>\\n </section>\\n </div>\",\"PeriodicalId\":10346,\"journal\":{\"name\":\"Clinical Endocrinology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-07-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Endocrinology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/cen.15112\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cen.15112","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
摘要
目的：本研究旨在了解肢端肥大症缓解时间对肢端肥大症患者生存期的影响：本研究旨在了解肢端肥大症缓解时间对肢端肥大症患者生存期的影响：这项横断面研究使用了英国肢端肥大症登记处的数据。我们认为，在确诊肢端肥大症后，生长激素控制在≤2 μg/L时，肢端肥大症病情缓解。我们使用加速失败时间模型来评估缓解时间对肢端肥大症患者生存率的影响：研究对象包括3569名肢端肥大症患者，确诊年龄中位数为47.3（36.5-57.8）岁，女性占48%，白人占多数（61%）。肢端肥大症首次缓解的人数为 2472 人，首次缓解的中位时间为 1.92（0.70-6.58）年。研究发现，肢端肥大症的首次缓解时间对患者的生存率有显著影响（p 结论：肢端肥大症的首次缓解时间对患者的生存率有显著影响：总之，这项针对肢端肥大症患者的人群研究显示，加快缓解时间、手术干预和使用 SMA 治疗与改善生存结果有关。
Time to first remission and survival in patients with acromegaly: Evidence from the UK Acromegaly Register Study (UKAR)
Objective
This study aimed to understand the effect of time to remission of acromegaly on survival in people living with acromegaly.
Design, Patients and Measurement
This cross-sectional study used data from the UK Acromegaly Register. We considered remission of acromegaly growth hormone controlled at ≤2 μg/L following the diagnosis of acromegaly. We used the accelerated failure time model to assess the effect of time to remission on survival in acromegaly.
Results
The study population comprises 3569 individuals with acromegaly, with a median age of diagnosis of 47.3 (36.5–57.8) years, 48% females and a majority white population (61%). The number of individuals with the first remission of acromegaly was 2472, and the median time to first remission was 1.92 (0.70–6.58) years. In this study, time to first remission in acromegaly was found to have a significant effect on survival (p < .001); for every 1-year increase in time to first remission, there was a median 1% reduction in survival in acromegaly. In an analysis adjusted for covariates, the survival rate was 52% higher (p < .001) in those who underwent surgery as compared to those who did not have surgery, 18% higher (p = .01) in those who received treatment with somatostatin analogues (SMA) as compared to those with dopamine agonists and 21% lower (p < .001) in those who received conventional radiotherapy as compared to those who did not receive radiotherapy.
Conclusion
In conclusion, this population-based study conducted in patients with acromegaly revealed that faster remission time, surgical intervention and treatment with SMA are linked to improved survival outcomes.
期刊介绍：
Clinical Endocrinology publishes papers and reviews which focus on the clinical aspects of endocrinology, including the clinical application of molecular endocrinology. It does not publish papers relating directly to diabetes care and clinical management. It features reviews, original papers, commentaries, correspondence and Clinical Questions. Clinical Endocrinology is essential reading not only for those engaged in endocrinological research but also for those involved primarily in clinical practice.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
